The cup-with-handle base is a common chart formation. But if a stock climbs up a cup’s U-shaped pattern without pulling back, it can form a variation called the cup-without-handle base. Several IBD 50 names, including growth stocks, have formed cup bases on their weekly MarketSurge charts.
Ubiquiti (UI) is nearing an entry point of a cup base while Sterling Infrastructure (STRL) is in a buy zone. Meanwhile, eyedrops maker Harrow (HROW) and Stoke Therapeutics (STOK) are both setting up with quarterly reports due out soon.
↑
X
This video file cannot be played.(Error Code: 102630)
How To Buy Stocks: Cup Base
See All Videos
NOW PLAYING
How To Buy Stocks: Cup Base
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
These Growth Stocks Nearing Buy Points
Harrow stock is nearing a 54.85 buy point from a first-stage cup base. Its relative strength line reached a 52-week high, as shown by the blue dot on its chart.
Harrow is expected to announce fourth-quarter results on Monday after the market close.
FactSet forecasts call for fourth-quarter profit of 37 cents per share on $90 million sales. On Feb. 2, Harrow reiterated its full-year 2025 revenue range outlook of $270 million to $280 million. It makes prescription eyedrops to treat cataracts, macular degeneration, glaucoma and retinal diseases.
Ubiquiti is climbing in a cup base with an 803.60 buy point. Shares soared after the company reported fiscal second-quarter profit of $3.88 per share, or 70% growth, on sales of $814.9 million on Feb. 6.
Ubiquiti stock trades with an average daily volume of around 105,200 shares, which is on the thin side. Ubiquiti develops networking and information technology infrastructure, as well as switches, routers and physical security devices.
IBD Newsletters
Get exclusive IBD analysis and actionable news daily.
SIGN UP NOW!
IBD Newsletters
Get exclusive IBD analysis and actionable news daily.
*
How To Invest
*
Market Prep
*
Tech Report
Please enter a valid email address
Please select a newsletter
GO
Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use
x
Thank You!
You will now receive IBD Newsletters
ALL DONE!
Something Went Wrong!
Please contact customer service
CLOSE
Data Center Infrastructure Name In Buy Zone
Stoke Therapeutics formed a cup base with a 37.34 entry point. The genetics-based medicines developer attempted a breakout on Monday but the breakout faded. The company has not been profitable and analysts call for a fourth-quarter loss of 74 cents per share. And full-year 2026 estimates see it losing $3.13 per share.
Next, Sterling Infrastructure is in the buy zone up to 440.10 of a first-stage cup base with a 419.14 entry point. On Wednesday, the company reported fourth-quarter adjusted earnings of $3.08 per share with revenue of $755.6 million.
Sterling also gave a full-year 2026 expected revenue range of $3.05 billion to $3.2 billion and forecasts profit at a range of $13.45 per share to $14.05 per share. The company provides infrastructure services to data centers as well as for roads, bridges and buildings.
Tarsus Pharmaceuticals (TARS) stock was on the IBD 50 but fell off after Wednesday’s 3.2% drop. Tarsus gapped up nearly 8% after the eye drops maker reported its fourth-quarter results late Monday. It is building the right side of a cup base with an 85.25 buy point.
The company’s fourth-quarter sales jumped 128% and its loss dwindled to 20 cents a share. Analysts call for a full-year 2026 loss of 63 cents per share then a profit of $3.05 per share in 2027. Tarsus makes Xdemvy, an eyedrop used to treat an eyelid inflammation condition caused by a type of mites.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
**YOU MAY ALSO LIKE: **
Discover Profitable Trades Each Day With MarketDiem. See How.
What To Do When Growth Stocks Backtrack To Test Buy Points
Learn How To Time The Market With IBD’s ETF Market Strategy
Looking For Market Insights? Check Out Our Live Daily Segment | Stocks To Watch
Learn How To Buy Stocks | Stocks To Watch
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.
The cup-with-handle base is a common chart formation. But if a stock climbs up a cup’s U-shaped pattern without pulling back, it can form a variation called the cup-without-handle base. Several IBD 50 names, including growth stocks, have formed cup bases on their weekly MarketSurge charts.
Ubiquiti (UI) is nearing an entry point of a cup base while Sterling Infrastructure (STRL) is in a buy zone. Meanwhile, eyedrops maker Harrow (HROW) and Stoke Therapeutics (STOK) are both setting up with quarterly reports due out soon.
This video file cannot be played.(Error Code: 102630)
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
These Growth Stocks Nearing Buy Points
Harrow stock is nearing a 54.85 buy point from a first-stage cup base. Its relative strength line reached a 52-week high, as shown by the blue dot on its chart.
Harrow is expected to announce fourth-quarter results on Monday after the market close.
FactSet forecasts call for fourth-quarter profit of 37 cents per share on $90 million sales. On Feb. 2, Harrow reiterated its full-year 2025 revenue range outlook of $270 million to $280 million. It makes prescription eyedrops to treat cataracts, macular degeneration, glaucoma and retinal diseases.
Ubiquiti is climbing in a cup base with an 803.60 buy point. Shares soared after the company reported fiscal second-quarter profit of $3.88 per share, or 70% growth, on sales of $814.9 million on Feb. 6.
Ubiquiti stock trades with an average daily volume of around 105,200 shares, which is on the thin side. Ubiquiti develops networking and information technology infrastructure, as well as switches, routers and physical security devices.
IBD Newsletters
Get exclusive IBD analysis and actionable news daily.
IBD Newsletters
Get exclusive IBD analysis and actionable news daily.
Please enter a valid email address
Please select a newsletter
Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use
Thank You!
You will now receive IBD Newsletters
Something Went Wrong!
Please contact customer service
Data Center Infrastructure Name In Buy Zone
Stoke Therapeutics formed a cup base with a 37.34 entry point. The genetics-based medicines developer attempted a breakout on Monday but the breakout faded. The company has not been profitable and analysts call for a fourth-quarter loss of 74 cents per share. And full-year 2026 estimates see it losing $3.13 per share.
Next, Sterling Infrastructure is in the buy zone up to 440.10 of a first-stage cup base with a 419.14 entry point. On Wednesday, the company reported fourth-quarter adjusted earnings of $3.08 per share with revenue of $755.6 million.
Sterling also gave a full-year 2026 expected revenue range of $3.05 billion to $3.2 billion and forecasts profit at a range of $13.45 per share to $14.05 per share. The company provides infrastructure services to data centers as well as for roads, bridges and buildings.
Tarsus Pharmaceuticals (TARS) stock was on the IBD 50 but fell off after Wednesday’s 3.2% drop. Tarsus gapped up nearly 8% after the eye drops maker reported its fourth-quarter results late Monday. It is building the right side of a cup base with an 85.25 buy point.
The company’s fourth-quarter sales jumped 128% and its loss dwindled to 20 cents a share. Analysts call for a full-year 2026 loss of 63 cents per share then a profit of $3.05 per share in 2027. Tarsus makes Xdemvy, an eyedrop used to treat an eyelid inflammation condition caused by a type of mites.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
**YOU MAY ALSO LIKE: **
Discover Profitable Trades Each Day With MarketDiem. See How.
What To Do When Growth Stocks Backtrack To Test Buy Points
Learn How To Time The Market With IBD’s ETF Market Strategy
Looking For Market Insights? Check Out Our Live Daily Segment | Stocks To Watch
Learn How To Buy Stocks | Stocks To Watch